
Opinion|Videos|March 7, 2025
Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence
Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of patient education to improve adherence and ensure positive treatment outcomes.
Advertisement
Episodes in this series

- What proactive measures can health care teams implement to manage adverse events associated with BTK inhibitors, ensuring both treatment adherence and patient quality of life?
- How can oncologists better educate patients about BTK inhibitors to improve adherence and support positive treatment outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
2
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
3
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5